Syntis Bio, a new clinical-stage biopharmaceutical company, has officially launched.
Based in Boston, USA, the company aims to develop oral therapies for a wide range of conditions, including rare genetic disorders and common metabolic diseases like obesity.
Lead program SYNT-101 is a once-daily pill designed to mimic gastric bypass surgery by blocking nutrient absorption. The company plans to initiate a clinical program for the candidate next year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze